January 2, 2018 09:43 AM ESTUpdated November 19, 05:51 AM

Star drugs like BMS' Opdivo, AstraZeneca's Lynparza will get speedy OKs in China this year, new report predicts

Amber Tong

Now that China has revamped its drug review process to speed things up for developers, a new report predicts that Bristol-Myers Squibb $BMY, AstraZeneca …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Star drugs like BMS' Opdivo, AstraZeneca's Lynparza will get speedy OKs in China this year, new report predicts

Amber Tong

Sign up to read this article for free.

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Novo Nordisk’s once-daily hemophilia drug Alhemo approved in US

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

GSK's Zejula-Jemperli combo in ovarian cancer hits primary endpoint, misses on overall survival

Exclusive: Florida cancer biotech raises $100M Series A

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Star drugs like BM­S' Op­di­vo, As­traZeneca's Lyn­parza will get speedy OKs in Chi­na this year, new re­port pre­dicts

Amber Tong

Sign up to read this article for free.

more like this

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Star drugs like BMS' Opdivo, AstraZeneca's Lynparza will get speedy OKs in China this year, new report predicts

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Novo Nordisk’s once-daily hemophilia drug Alhemo approved in US

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

GSK's Zejula-Jemperli combo in ovarian cancer hits primary endpoint, misses on overall survival

Exclusive: Florida cancer biotech raises $100M Series A

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.